CircNova, a Michigan-based biotech startup, has secured $3.3 million in seed funding for its innovative technology that leverages AI to develop therapies targeting circular RNA—newly discovered structures that have potential in addressing complex health issues. The company, co-founded by Crystal Brown, utilizes its proprietary NovaEngine, which predicts circular RNA structures using deep learning algorithms. With collaborations through a wet lab and the University of Michigan, CircNova aims to create treatments for diseases like ovarian cancer and neurodegenerative conditions, marking a significant advancement in biotech research and application.
CircNova not only has its NovaEngine, which it says is the first in the world to be able to predict circular RNA structures, but it also has a wet lab.
We can reverse engineer. We can go from sequence to structure. We can go from structure to sequence when developing the molecule.
The goal is to treat diseases we haven't treated so far, things like ovarian cancer, triple-negative breast cancer, neurodegenerative diseases, rare genetic diseases.
The development holds promise as a new method to quickly develop therapies for conditions that currently have no drug treatments.
Collection
[
|
...
]